NASDAQ:PHAR

Pharming Group - PHAR Stock Forecast, Price & News

$13.45

+0.08 (+0.60%)

(As of 02/1/2023 12:00 AM ET)

Add

Compare

Today's Range: $13.45
▼
$14.16
50-Day Range: $10.56
▼
$14.78
52-Week Range: $6.10
▼
$15.00

Volume: 8,468 shs
Average Volume: 3,524 shs
Market Capitalization: $878.02 million

P/E Ratio: 32.81
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Pharming Group (NASDAQ:PHAR) Stock

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHAR Stock News Headlines

January 19, 2023 | marketwatch.com

Hereditary Angioedema Treatment Market 2023 : Company Profile Analysis, Industry Segmentation, Opportunity Assessment and Forecast by 2028

December 15, 2022 | markets.businessinsider.com

Pharming Reports Positive Interim Data From Study Of Leniolisib In Rare Primary Immunodeficiency

February 2, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now!

December 7, 2022 | seekingalpha.com

Pharming reports publishing of phase 3 data of rare immunodeficiency disorder drug

December 7, 2022 | finanznachrichten.de

Pharming Group NV: Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood

December 7, 2022 | markets.businessinsider.com

Pharming : Positive Data From Phase 3 Study Of Leniolisib In Rare Primary Immunodeficiency Published

December 7, 2022 | marketwatch.com

Pharming Group's Leniolisib Phase 3 Study Shows Positive Data

December 1, 2022 | finance.yahoo.com

Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?

February 2, 2023 | Tradewins (Ad)

Know Your Profit Potential BEFORE You Trade!

November 24, 2022 | finanznachrichten.de

Pharming Group N.V.: Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting

November 3, 2022 | finanznachrichten.de

Pharming Group N.V.: Pharming to present at Stifel Healthcare Conference

November 3, 2022 | finance.yahoo.com

Pharming to present at Jefferies Healthcare Conference

November 2, 2022 | finance.yahoo.com

Pharming to present at Stifel Healthcare Conference

October 28, 2022 | finance.yahoo.com

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

October 27, 2022 | finanznachrichten.de

Pharming Group N.V.: Pharming Group reports earnings for the first nine months of 2022

October 27, 2022 | finance.yahoo.com

Pharming Group reports earnings for the first nine months of 2022

October 18, 2022 | finance.yahoo.com

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

October 12, 2022 | finanznachrichten.de

Pharming Group N.V.: Pharming Group Notice of Q3 Results

October 11, 2022 | marketwatch.com

Pharming Group Submits Marketing Authorization Application for Leniolisib

September 28, 2022 | markets.businessinsider.com

European Shares Slump As Risk Appetite Wanes

September 28, 2022 | nasdaq.com

Pharming: FDA Accepts Leniolisib NDA For Priority Review To Treat APDS

September 28, 2022 | finance.yahoo.com

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

September 7, 2022 | finance.yahoo.com

CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference

August 6, 2022 | seekingalpha.com

Pharming Group N.V.'s (PHGUF) CEO Sijmen de Vries on First Half 2022 Results - Earnings Call Transcript

August 1, 2022 | finance.yahoo.com

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

July 25, 2022 | finanznachrichten.de

Pharming Group N.V.: Pharming Group Notice of H1 2022 Results

July 25, 2022 | finance.yahoo.com

Pharming Group Notice of H1 2022 Results

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHAR Company Calendar

Today: 2/02/2023
Next Earnings (Estimated): 3/16/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PHAR
CUSIP: N/A
CIK: 1828316
Web: www.pharming.com
Phone: 31-71-524-7400
Fax: N/A
Employees: 262
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.41
Trailing P/E Ratio: 32.81
Forward P/E Ratio: 269.00
P/E Growth: N/A
Net Income: $16 million
Net Margins: 14.90%
Pretax Margin: N/A
Return on Equity: 8.98%
Return on Assets: 4.51%

Debt

Debt-to-Equity Ratio: 0.60
Current Ratio: 5.40
Quick Ratio: 4.68

Sales & Book Value

Annual Sales: $198.87 million
Price / Sales: 4.42
Cash Flow: $0.55 per share
Price / Cash Flow: 24.36
Book Value: $2.97 per share
Price / Book: 4.53

Miscellaneous

Outstanding Shares: 65,280,000
Free Float: 63,929,000
Market Cap: $878.02 million
Optionable: Not Optionable
Beta: 0.22

Key Executives

Dr. Sijmen de Vries M.B.A. (Age 63)
M.D., MBA, Pres, CEO & Exec. Director
Comp: $1.2M

Dr. Bruno M. L. Giannetti (Age 70)
Consultant

Mr. Jeroen Wakkerman (Age 53)
Chief Financial Officer

Ms. Mireille Sanders M.Sc. (Age 54)
Chief Operations Officer

Susanne Embleton
Investor Relations Mang.

Mr. Ruud Van Outersterp (Age 58)
Chief Ethics & Compliance Officer

Mr. Anurag Relan (Age 50)
Chief Medical Officer

Mr. Stephen Toor (Age 51)
Chief Commercial Officer & GM of Americas

Key Competitors

View All Competitors

Insiders & Institutions

Cowen Prime Advisors LLC
Bought 4,910 shares on 2/1/2023
Ownership: 0.033%

View All Institutional Transactions

PHAR Stock - Frequently Asked Questions

How have PHAR shares performed in 2023?: Pharming Group's stock was trading at $11.03 at the beginning of 2023. Since then, PHAR stock has increased by 21.9% and is now trading at $13.45.
View the best growth stocks for 2023 here.
When is Pharming Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our PHAR earnings forecast.
What is Pharming Group's stock symbol?: Pharming Group trades on the NASDAQ under the ticker symbol "PHAR."
Who are Pharming Group's major shareholders?: Pharming Group's stock is owned by many different institutional and retail investors. Top institutional investors include Cowen Prime Advisors LLC (0.03%).

How do I buy shares of Pharming Group?: Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pharming Group's stock price today?: One share of PHAR stock can currently be purchased for approximately $13.45.
How much money does Pharming Group make?: Pharming Group (NASDAQ:PHAR) has a market capitalization of $878.02 million and generates $198.87 million in revenue each year. The company earns $16 million in net income (profit) each year or $0.41 on an earnings per share basis.
How many employees does Pharming Group have?: The company employs 262 workers across the globe.
How can I contact Pharming Group?: Pharming Group's mailing address is DARWINWEG 24, LEIDEN P7, 2333 CR. The official website for the company is www.pharming.com. The company can be reached via phone at 31-71-524-7400 or via email at investor@pharming.com.

This page (NASDAQ:PHAR) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial